RYTM - Rhythm Pharmaceuticals

-

$undefined

N/A

(N/A)

Rhythm Pharmaceuticals NasdaqGM:RYTM Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Location: 222 Berkeley Street, Boston, MA, 02116, United States | Website: https://rhythmtx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.88B

Cash

314.5M

Avg Qtr Burn

-28.37M

Short % of Float

9.84%

Insider Ownership

0.62%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

IMCIVREE™ (Setmelanotide) Details
Rare genetic disease, Bardet-Biedl syndrome

Approved

Quarterly sales

Approved

Quarterly sales

IMCIVREE™ (Setmelanotide) Details
Acquired Hypothalamic Obesity (HO)

sNDA

Submission

NDA

FDA meeting

IMCIVREE™ (Setmelanotide) Details
Congenital Hypothalamic Obesity (HO)

Phase 3

Data readout

IMCIVREE™ (Setmelanotide) Details
Genetically [POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1] caused MC4R pathway diseases

Phase 3

Data readout

Phase 2

Data readout

IMCIVREE™ (Setmelanotide) Details
Prader-Willi syndrome (PWS)

Phase 2

Data readout

Bivamelagon Details
Acquired Hypothalamic Obesity (HO)

Phase 2

Data readout

RM-718 Details
Acquired hypothalamic obesity (HO)

Phase 1

Data readout